Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 - Ireland

SAFETY DATA SHEET



AQUATOP 2760-03 - All variants

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier Product name

: AQUATOP 2760-03 - All variants

1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use: Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091. e-mail address of person : Prod-safe@teknos.com responsible for this SDS

National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

National advisory body/Poison Centre

Telephone number : National Poisons Information Centre: 01 809 2566

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Skin Sens. 1, H317 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms



Signal word	Varning	
Hazard statements	l317 - May cause an allergic skin reaction. l412 - Harmful to aquatic life with long lasting effects.	
Precautionary statements		
Prevention	2280 - Wear protective gloves. 2273 - Avoid release to the environment. 2261 - Avoid breathing vapour.	
Response	P362 + P364 - Take off contaminated clothing and wash it before reuse P302 + P352 - IF ON SKIN: Wash with plenty of water.	ł_
Storage	lot applicable.	
Disposal	2501 - Dispose of contents and container in accordance with all local, reational and international regulations.	egional,

SECTION 2: Hazards identification

Hazardous ingredients	: Contains: 3-iodo-2-propynyl-butyl carbamate; 2,4,7,9-tetramethyl-5-decyne-4,7-diol; adipohydrazide and 4,5-dichloro-2-octyl-2H-isothiazol-3-one
Supplemental label elements	: Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist. Contains biocidal products for dry film and in-can preservation: IPBC and DCOIT and BIT and MIT and OIT. Risk of skin sensitisation.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:
2.3 Other hazards	
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	: This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	: None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures	: Mixture				
Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
Manium dioxide	REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7	≥10 - ≤25	Carc. 2, H351 (inhalation)	-	[1] [*]
2-Butoxyethanol	REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0	<1	Acute Tox. 4, H302 Acute Tox. 3, H331 Skin Irrit. 2, H315 Eye Irrit. 2, H319	ATE [Oral] = 1200 mg/kg ATE [Inhalation (vapours)] = 3 mg/l	[1] [2]
3-iodo-2-propynyl-butyl carbamate	EC: 259-627-5 CAS: 55406-53-6 Index: 616-212-00-7	≤0.2	Acute Tox. 4, H302 Acute Tox. 3, H331 Eye Dam. 1, H318 Skin Sens. 1, H317 STOT RE 1, H372 (larynx) Aquatic Acute 1, H400 Aquatic Chronic 1, H410	ATE [Oral] = 400 mg/kg ATE [Inhalation (dusts and mists)] = 0.67 mg/l M [Acute] = 10 M [Chronic] = 1	[1]
2,4,7,9-tetramethyl- 5-decyne-4,7-diol	REACH #: 01-2119954390-39 EC: 204-809-1 CAS: 126-86-3	≤0.3	Eye Dam. 1, H318 Skin Sens. 1B, H317 Aquatic Chronic 3, H412	-	[1]
adipohydrazide	REACH #: 01-2119962900-36 EC: 213-999-5 CAS: 1071-93-8	≤0.3	Skin Sens. 1, H317 Aquatic Chronic 2, H411	-	[1]
4,5-dichloro-2-octyl-2H- isothiazol-3-one	EC: 264-843-8 CAS: 64359-81-5 Index: 613-335-00-8	≤0.022	Acute Tox. 4, H302 Acute Tox. 2, H330 Skin Corr. 1, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400	ATE [Oral] = 567 mg/kg ATE [Inhalation (dusts and mists)] = 0.16 mg/l Skin Corr. 1, H314:	[1]
Date of issue/Date of revision	: 30/08/2023 Dat	e of previous is	sue : 04/10/2022	Version : 2	2/17
AQUATOP 2760-03 - All variants			Label No :#96	64	

			Aquatic Chronic 1, H410 EUH071	$C \ge 5\%$ Skin Irrit. 2, H315: $0.025\% \le C < 5\%$ Eye Dam. 1, H318: $C \ge 3\%$ Eye Irrit. 2, H319: $0.025\% \le C < 3\%$ Skin Sens. 1, H317: $C \ge 0.0015\%$ M [Acute] = 100 M [Chronic] = 100	
1,2-benzisothiazol-3(2H)- one	EC: 220-120-9 CAS: 2634-33-5 Index: 613-088-00-6	<0.05	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Acute 1, H400	ATE [Oral] = 1020 mg/kg Skin Sens. 1, H317: C ≥ 0.05% M [Acute] = 1	[1]
2-methyl-2H-isothiazol- 3-one	EC: 220-239-6 CAS: 2682-20-4	<0.01	Acute Tox. 3, H301 Acute Tox. 3, H311 Acute Tox. 2, H330 Skin Corr. 1B, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 100 mg/kg ATE [Dermal] = 300 mg/kg ATE [Inhalation (dusts and mists)] = 0.11 mg/l Skin Sens. 1, H317: C $\geq 0.0015\%$ M [Acute] = 10 M [Chronic] = 1	[1]
reaction mass of: 5-chloro- 2-methyl-4-isothiazolin- 3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol- 3-one [EC no. 220-239-6] (3:1)	CAS: 55965-84-9 Index: 613-167-00-5	<0.001	Acute Tox. 3, H301 Acute Tox. 2, H310 Acute Tox. 2, H330 Skin Corr. 1C, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 53 mg/ kg ATE [Dermal] = 50 mg/kg ATE [Inhalation (vapours)] = 0.5 mg/l Skin Corr. 1C, H314: $C \ge 0.6\%$ Eye Dam. 1, H318: $C \ge 0.6\%$ Eye Irrit. 2, H319: $0.06\% \le C < 0.6\%$ Skin Sens. 1, H317: $C \ge 0.0015\%$ M [Acute] = 100 M [Chronic] = 100	[1]
			See Section 16 for the full text of the H statements declared above.		

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

<u>Type</u>

7 Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter \leq 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid n	neasures
Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Skin contact	: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

4.2 Most important symptoms and effects, both acute and delayed

Over-exposure signs/symptoms

Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.
4.3 Indication of any im	mediate medical attention and special treatment needed

Notes to physician	 Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	: No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media Suitable extinguishing media	: Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	: None known.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture
 In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

: 30/08/2023 Date of previous issue

:04/10/2022

SECTION 5: Firefighting measures		
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide metal oxide/oxides	
5.3 Advice for firefighters		
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.	
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.	

SECTION 6: Accidental release measures

6.1 Personal precautions, pro	ote	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.
6.3 Methods and material for	СС	ontainment and cleaning up
Omell en ill		Ctan look if without vick. Move containers from chill area. Dilute with water and men

Small spill	: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	: Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spill product.
6.4 Reference to other sections	: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Avoid release to the environment. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
---------------------	--

Date of issue/Date of revision	: 30/08/2023	Date of previous issue	: 04/10/2022	Version	:2	5/17
AQUATOP 2760-03 - All variants				Label No	4 9664	ł

SECTION 7: Handling and storage

Advice on general	
occupational hygiene	

: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific	: Not available.

Industri solutions

SECTION 8: Exposure controls/personal protection

required.

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values
2-Butoxyethanol	NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU derived Occupational Exposure Limit Values
	OELV-8hr: 20 ppm 8 hours. OELV-8hr: 98 mg/m ³ 8 hours. OELV-15min: 50 ppm 15 minutes. OELV-15min: 246 mg/m ³ 15 minutes.

Biological exposure indices

Product/ingredient name	Exposure indices	
2-Butoxyethanol	NAOSH (Ireland, 1/2011) BMGV: 200 mg/g creatinine, BAA [in urine]. Sampling time: end shift - As soon as possible after exposure ceases.	
procedures European Stat assessment of values and me atmospheres - of exposure to (Workplace at for the measure	build be made to monitoring standards, such as the following: Indard EN 689 (Workplace atmospheres - Guidance for the f exposure by inhalation to chemical agents for comparison with limit easurement strategy) European Standard EN 14042 (Workplace Guide for the application and use of procedures for the assessment chemical and biological agents) European Standard EN 482 mospheres - General requirements for the performance of procedures rement of chemical agents) Reference to national guidance methods for the determination of hazardous substances will also be	

DNELs/DMELs

Product/ingredient name	Туре	Exposure	Value	Populatior	n Effects
2-Butoxyethanol	DNEL	Long term Oral	6.3 mg/kg bw/day	General population	Systemic
	DNEL	Short term Oral	26.7 mg/ kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	59 mg/m³	General population	Systemic
	DNEL	Long term Inhalation	98 mg/m³	Workers	Systemic
	DNEL	Short term Inhalation	147 mg/m³	General population	Local
ate of issue/Date of revision	: 30/08/2023	Date of previous issue	: 04/10/2	022	Version : 2 6/17
QUATOP 2760-03 - All variants				L	.abel No : <mark>4</mark> 9664

DNEL Short term 246 mg/m ² Workers Local 3-lodo-2-propynyl-butyl carbamate DNEL Short term 426 mg/m ² General Systemic 3-lodo-2-propynyl-butyl carbamate DNEL Short term 1091 mg/ Workers Systemic 3-lodo-2-propynyl-butyl carbamate DNEL Short term 0.023 mg/ Workers Systemic 0.41,7,9-letramethyl-5-decyne-4,7-diol DNEL Long term 1.16 mg/m ² Workers Local 2,4,7,9-letramethyl-5-decyne-4,7-diol DNEL Long term 1.16 mg/m ² Workers Systemic 0,24,7,9-letramethyl-5-decyne-4,7-diol DNEL Long term 1.16 mg/m ² Workers Systemic 0,43,7,9-letramethyl-5-decyne-4,7-diol DNEL Long term 0.35 mg/s General Systemic DNEL Long term 0.35 mg/s General Systemic Systemic DNEL Long term 0.35 mg/s General Systemic Systemic DNEL Long term 0.35 mg/s General Systemic <t< th=""><th>ECTION 8: Exposure cont</th><th>rols/p</th><th>personal prote</th><th>ction</th><th></th><th></th></t<>	ECTION 8: Exposure cont	rols/p	personal prote	ction		
DNELShort term Inhalation426 mg/m² populationSystemic population3-lodo-2-propynyl-butyl carbamateDNELShort term Inhalation1091 mg/ m²WorkersSystemic3-lodo-2-propynyl-butyl carbamateDNELLong term Inhalation0.023 mg/ m²WorkersSystemicDNELShort term Inhalation1.16 mg/m²WorkersSystemicDNELShort term Inhalation1.16 mg/m²WorkersLocalDNELLong term Inhalation1.16 mg/m²WorkersSystemicDNELLong term Inhalation1.16 mg/m²WorkersSystemicDNELLong term Dermal Inhalation2.5 mg/ Kg bw/dayGeneral opulationSystemicDNELLong term Dermal Inhalation0.5 mg/kg bw/dayGeneral opulationSystemicDNELLong term Dermal Inhalation0.5 mg/kg bw/dayGeneral opulationSystemicDNELShort term Cral Inhalation0.5 mg/kg bw/dayGeneral opulationSystemicDNELShort term Dermal Inhalation0.5 mg/kg bw/dayGeneral opulationSystemicDNELShort term Dermal Inhalation1.76 mg/m²WorkersSystemicDNELShort term Dermal Inhalation1.76 mg/m²WorkersSystemicDNELNort term DNELLong term Dermal Inhalation1.76 mg/m²WorkersSystemicDNELNort term DNELLong term Dermal Inhalation0.36 mg/ MorkersS		DNEL		246 mg/m ³	Workers	Local
JackbornInhalation Inhalation Inhalation Inhalation InhalationInhalation Instruct Inhalation InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InhalationInstruct Instruct InstructInstruct Instruct InstructInstruct Instruct InstructInstruct Instr				126 mg/m^3	Conoral	Svetemie
DNELShort term inhalation109 fmg/ m²WorkersSystemic3-lodo-2-propynyt-butyl carbamateDNELLong term inhalation0.023 mg/ m²WorkersSystemicDNELShort term inhalation1.16 mg/m²WorkersLocalDNELShort term inhalation1.16 mg/m²WorkersLocalDNELLong term Dermal inhalation1.16 mg/m²WorkersSystemicDNELLong term Dermal inhalation2.5 mg/kg bW/dayWorkersSystemicDNELLong term Dermal inhalation0.25 mg/kg bW/dayWorkersSystemicDNELLong term Dermal inhalation0.25 mg/kg bW/dayGeneral populationSystemicDNELLong term Dermal inhalation0.45 mg/kg bW/dayGeneral populationSystemicDNELLong term Dermal inhalation0.5 mg/kg bW/dayGeneral populationSystemicDNELShort term Dermal inhalation0.5 mg/kg bW/dayGeneral populationSystemicDNELShort term Dermal inhalation1.5 mg/kg bW/dayWorkersSystemicDNELShort term inhalation1.5 mg/kg bW/dayWorkersSystemicDNELLong term inhalation1.76 mg/m² bW/dayWorkersSystemicDNELLong term inhalation1.75 mg/m² bW/dayWorkersSystemicDNELLong term inhalation0.43 mg/m² bW/daySystemicSystemicDNELLong term inhal		DINEL		420 mg/m		Systemic
3-iodo-2-propynyl-butyl carbamate Inhalation Inhalation m ² mataliation m ² m ² 0.02 mg/m Workers Systemic 2.4,7,9-tetrametryl-5-decyne-4,7-diol DNEL Short term 1.16 mg/m Workers Systemic 2.4,7,9-tetrametryl-5-decyne-4,7-diol DNEL Long term 1.16 mg/m Workers Systemic 2.4,7,9-tetrametryl-5-decyne-4,7-diol DNEL Long term 1.16 mg/m Workers Systemic DNEL Long term 1.05 mg/m General (bW/day Systemic Systemic DNEL Long term 0.15 mg/m General (bW/day Systemic Systemic DNEL Long term 0.5 mg/m General (bW/day Systemic Systemic DNEL Long term 1.5 mg/m Workers Systemic Systemic DNEL Short term Dermai 1.5 mg/m Workers Systemic DNEL Long term 1.5 mg/m Workers Systemic DNEL Long term 1.5 mg/m Workers Systemic Inhalation DNEL <td></td> <td>DNEL</td> <td></td> <td>1091 ma/</td> <td></td> <td>Systemic</td>		DNEL		1091 ma/		Systemic
And a constraint of the second seco						- ,
DNEL Inhalation DNEL Inhalation DNEL Inhalation DNEL Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal 	3-iodo-2-propynyl-butyl carbamate	DNEL	Long term	0.023 mg/	Workers	Systemic
Inhalation Inhalation InhalationInformation InformationInformation Information2,4,7,9-tetramethyl-5-decyne-4,7-diolDNEL Iong term DNEL Iong term Inhalation DNEL Iong term Inhalation DNEL Iong term Ionalition DNEL Iong term Oral Ionalition Ionalition Ionalition DNEL Iong term Ionalition DNEL Iong term Ionalition DNEL Iong term Oral Ionalition DNEL Iong term Oral Ionalition DNEL Iong term Oral Ionalition DNEL Iong term Oral Ionalition DNEL Iong term Oral Ionalition DNEL Iong term Oral Iong term Ionalition DNEL Iong term Oral Iong term Ionaliti						
DNEL inhalation DNEL inhalation DNEL Long term oral inhalation DNEL Long term Dermal DNEL Long term Dermal Miday DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL Systemic population DNEL DNEL DNEL Long term Dermal DNEL DNEL Short term Oral DNEL DNEL DNEL Short term Oral DNEL		DNEL		0.07 mg/m ³	Workers	Systemic
Inhalation Long term Inhalation DNEL Long term Oral DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Short term Oral DNEL Short term Oral DNEL Short term Dermal DNEL Short term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL Lon				$1.16 mg/m^{3}$	Workoro	
DNEL Inhalation Inhalation DNEL Long term Oral DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Short term Oral DNEL DNEL Short term Oral DNEL DNEL Short term Oral DNEL DNEL Short term Oral DNEL DNEL DNEL Short term Oral DNEL <td></td> <td>DINEL</td> <td></td> <td>1.10 mg/m</td> <td>WOIKEIS</td> <td>LUCAI</td>		DINEL		1.10 mg/m	WOIKEIS	LUCAI
2.4,7,9-tetramethyl-5-decyne-4,7-dio DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL DNEL DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL D		DNEL		1.16 ma/m ³	Workers	Local
2,4,7,9-tetramethyl-5-decyne-4,7-diol DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Short term Dermal DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL DNEL Cong term 17.5 mg/m Workers Systemic population DNEL Long term 1.2 mg/m ² General population Systemic DNEL Long term DNEL Long term			-	5		
2,4,7,9-tetramethyl-5-decyne-4,7-diol DNEL Long term Oral 0,25 mg/ 0,25 mg/ 0,25 mg/ 10 MeL General population Systemic population DNEL Long term Dermal 0,43 mg/m 0,55 mg/ 10 MeL General population Systemic population DNEL Long term Dermal 0,5 mg/m 0,5 mg/m 10 MeL General population Systemic DNEL Short term Oral 0,5 mg/m 10 MeL General population Systemic DNEL Short term Oral 0,5 mg/m 10 MeL General population Systemic DNEL Short term Oral 0,5 mg/m 10 MeL General population Systemic DNEL Short term Dermal 1.5 mg/m 10 MeL General population Systemic DNEL Short term Dermal Inhalation 1.5 mg/m 10 MeL Workers Systemic DNEL Short term Dermal 1.76 mg/m ³ Workers Systemic 1,2-benzisothiazol-3(2H)-one DNEL Long term Dermal 0.445 mg/m ³ General population Systemic 1,2-benzisothiazol-3-0ne DNEL Long term Dermal 0.245 mg/m ³ General population Systemic 1,2-benzisothiazol-3-one DNEL Long term Oral 0.247 mg/m ³ General population Systemic 1.2-benzisothiazol-3-one DNEL Long term Oral <td></td> <td>DNEL</td> <td>Long term Dermal</td> <td></td> <td>Workers</td> <td>Systemic</td>		DNEL	Long term Dermal		Workers	Systemic
And the second					. .	
DNEL inhalationLong term Dermal kg bw/dayÖ.25 mg/ opulationGeneral opulationSystemic populationDNEL Long term Dermal inhalationDNEL bw/day0.75 mg/ General bw/dayGeneral opulationSystemic populationDNEL bw/dayDNEL DNELShort term Dermal inhalation0.75 mg/ General populationGeneral systemicSystemicDNEL bw/dayShort term Dermal inhalation0.75 mg/ generalGeneral populationSystemicDNEL bw/dayShort term Dermal inhalation1.5 mg/kg populationWorkersSystemicDNEL bort term inhalationShort term inhalation1.76 mg/m WorkersWorkersSystemicDNEL bort termDNEL bort termShort term inhalation1.76 mg/m WorkersWorkersSystemic1,2-benzisothiazol-3(2H)-oneDNEL DNEL bort termLong term inhalation17.5 mg/m WorkersWorkersSystemic1,2-benzisothiazol-3(2H)-oneDNEL DNEL bord term inhalationDNEL bord term inhalation0.345 mg/ md' WorkersGeneral systemicSystemic2-methyl-2H-isothiazol-3-oneDNEL DNEL bord term inhalation0.021 mg/ m' m' DNEL bord term inhalation0.021 mg/ m' m' deneral bord term bord/dayGeneral populationSystemic bord term population2-methyl-2H-isothiazol-3-oneDNEL DNEL bort term inhalation0.021 mg/ m' m' deneral bord term bord term bord term bord t	2,4,7,9-tetramethyl-5-decyne-4,7-diol	DNEL	Long term Oral			Systemic
NetNetLong term InhalationOpulation 0.43 mg/m'Opulation general populationSystemic populationDNELLong term Dermal0.5 mg/kgWorkersSystemic populationDNELShort term Oral0.75 mg/ by/dayGeneral populationSystemic populationDNELShort term Dermal0.75 mg/ by/dayGeneral populationSystemic populationDNELShort term Dermal0.75 mg/ bw/dayGeneral populationSystemic populationDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemic populationDNELShort term1.2 mg/m² bw/dayWorkersSystemic populationDNELLong term1.76 mg/m² bw/dayWorkersSystemic population1,2-benzisothiazol-3(2H)-oneDNELLong term1.5 mg/m² bw/dayWorkersSystemic population1,2-benzisothiazol-3(2H)-oneDNELLong term0.345 mg/ bopulationGeneral populationSystemic bopulation1,2-benzisothiazol-3(2H)-oneDNELLong term0.21 mg/ m²General populationSystemic bopulation2-methyl-2H-isothiazol-3-oneDNELLong term0.21 mg/ m²General populationSystemic bopulation2-methyl-2H-isothiazol-3-oneDNELShort term0.021 mg/ m²General populationSystemic bopulationDNELShort term0.021 mg/ m²General populationSystemic bopulationDNELSh			Long term Dermal			Systemic
DNEL Inhalation DNELLong term Long term Dermal DNEL0.43 mg/m² Dopulation Dopulation Dopulation DNELSystemic Systemic bw/day DNELSystemic Systemic bw/day DNELSystemic Systemic Bowday DopulationSystemic Systemic Systemic DopulationDNELShort term Oral DNEL0.57 mg/ SpoulationGeneral Systemic populationSystemic Systemic Systemic DopulationDNELShort term Dermal Inhalation DNELShort term Dermal Inhalation1.5 mg/kg WorkersWorkersSystemic SystemicadipohydrazideDNEL Long term InhalationShort term DNEL1.76 mg/m² WorkersWorkersSystemic Systemic1,2-benzisothiazol-3(2H)-oneDNEL DNELLong term Inhalation1.75 mg/m² WorkersWorkersSystemic Systemic1,2-benzisothiazol-3(2H)-oneDNEL DNELLong term Inhalation1.2 mg/m² WorkersGeneral SystemicSystemic Systemic1,2-benzisothiazol-3(2H)-oneDNEL DNELLong term Inhalation0.345 mg/ WorkersGeneral SystemicSystemic Systemic2-methyl-2H-isothiazol-3-oneDNEL DNELLong term Inhalation0.021 mg/ m² DNELGeneral DOUT mg/ WorkersSystemic Dopulation2-methyl-2H-isothiazol-3-oneDNEL DNELShort term DNEL0.021 mg/ m² DNELGeneral DOUT mg/ MorkersSystemic Dopulation2-methyl-2H-isothiazol-3-oneDNEL DNELShort term DNEL0.027 mg/ M² Short term		DIVLL	Long term Derma			Oysternie
Inhalation Long term Dermal bw/daypopulation bw/daypopulation population population population populationSystemic Systemic population population populationadipohydrazideDNEL DNELShort term Dermal Inhalation DNELShort term Dermal Inhalation DNEL1.5 mg/kg bw/dayGeneral population population populationSystemic populationadipohydrazideDNEL Inhalation DNELShort term Inhalation DNEL1.5 mg/kg bw/dayWorkersSystemic population1,2-benzisothiazol-3(2H)-oneDNEL DNELLong term Inhalation DNEL17.5 mg/m3 kg bw/dayWorkersSystemic population1,2-benzisothiazol-3(2H)-oneDNEL DNEL Long term Inhalation DNEL Long term Inhalation0.345 mg/ kg bw/day dow/dayGeneral population WorkersSystemic Systemic kg bw/day dow/day2-methyl-2H-isothiazol-3-oneDNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation m³ MorkersSystemic population MorkersSystemic Local population2-methyl-2H-isothiazol-3-oneDNEL DNEL Long term Oral Inhalation DNEL Long term Oral Inhalation DNEL Long term Oral DNEL Long term Oral DNEL D		DNEL	Long term			Systemic
bw/day bw/day (general populationSystemic population population populationadipohydrazide 1.2-benzisothiazol-3(2H)-oneDNEL DNEL Long term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation m³ MorkersSystemic Systemic Local DNEL Local DNEL Local m³ MorkersLocal Local2-methyl-2H-isothiazol-3-one (3:1)DNEL DNEL Short term Oral Inhalation DNEL Inhalation m³ Morkers0.02 mg/m³ General MorkersSystemic Systemic Local DNEL Local m³ MorkersLocal Local2-methyl-2H-isothiazol-3-one (3:1)DNEL DNEL Short term Oral Inhalation DNEL Inhalation0.02 mg/m³ m³			Inhalation	-	population	
DNELShort term Oral by UNEL0.75 mg/ kg bw/day DNELGeneral population General populationSystemic population General populationDNELShort term Dermal Inhalation1.29 mg/m³ DNELGeneral populationSystemic populationDNELShort term Dermal Inhalation1.5 mg/kg bw/dayWorkersSystemic populationadipohydrazideDNELShort term Inhalation1.7 mg/m³ UNKersWorkersSystemic population1.2-benzisothiazol-3(2H)-oneDNELLong term Inhalation17.5 mg/m³ UNKELWorkersSystemic Systemic1.2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ kg bw/day 0.966 mg/ WorkersGeneral SystemicSystemic Systemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.21 mg/ m³General populationSystemic Systemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationSystemic population2-methyl-2H-isothiazol-3-oneDNELShort term DNEL0.021 mg/ m³General populationSystemic population2-methyl-2H-isothiazol-3-oneDNELShort term DNEL0.021 mg/ m³General populationSystemic population2-methyl-2H-isothiazol-3-oneDNELShort term Oral DNEL0.021 mg/ m³General populationSystemic population2-methyl-2H-isothiazol-3-oneDNELShort term Oral DNEL0.023 mg/ <br< td=""><td></td><td>DNEL</td><td>Long term Dermal</td><td></td><td>Workers</td><td>Systemic</td></br<>		DNEL	Long term Dermal		Workers	Systemic
kg bw/day General population general population general populationSystemic population <br< td=""><td></td><td></td><td>Short town Oral</td><td></td><td>Concert</td><td>Our termine</td></br<>			Short town Oral		Concert	Our termine
DNELShort term Dermal (C,75 mg/)C,75 mg/ (C,75 mg/)Ceneral (C,75 mg/)Systemic populationDNELShort term (Inhalation DNELShort term Dermal (Inhalation DNEL1.5 mg/kg (WorkersSystemic populationDNELShort term Dermal (Inhalation DNEL1.5 mg/kg (WorkersWorkersSystemic populationadipohydrazideDNELLong term (Inhalation DNEL1.76 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal (Inhalation DNEL0.345 mg/ (kg bw/day) (MorkersGeneral (MorkersSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Dermal (Inhalation DNEL0.345 mg/ (kg bw/day) (MorkersGeneral (MorkersSystemic (Morkers2-methyl-2H-isothiazol-3-oneDNELLong term Dermal (Inhalation DNEL0.021 mg/ m³General (MorkersSystemic (Morkers2-methyl-2H-isothiazol-3-oneDNELLong term (Inhalation DNEL0.021 mg/ m³General (MorkersSystemic (MorkersDNELLong term (Inhalation (Inhalation DNELShort term (0.021 mg/ m³0.021 mg/ (MorkersGeneral (MorkersSystemic (MorkersDNELShort term (Inhalation0.021 mg/ (MorkersGeneral (MorkersSystemic (MorkersSystemic (MorkersDNELLong term (Inhalation0.021 mg/ (MorkersGeneral (MorkersSystemic (MorkersSystemic (MorkersDNELLong term (Inhalation<		DNEL	Short term Oral			Systemic
AdipohydrazideDNELShort term InhalationKg bw/day 1.29 mg/m³population populationSystemic populationadipohydrazideDNELShort term Dermal Inhalation1.76 mg/m³WorkersSystemicDNELLong term Inhalation1.76 mg/m³WorkersSystemicDNELLong term Inhalation1.75 mg/m³WorkersSystemicDNELLong term Inhalation0.345 mg/ kg bw/dayGeneral populationSystemic1.2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ kg bw/dayGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.21 mg/ m³General populationSystemic population2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationSystemic population2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationSystemic population2-methyl-2H-isothiazol-3-oneDNELLong term Onter0.021 mg/ m³General populationLocalDNELLong term Inhalation0.043 mg/ m³General populationSystemic populationDNELShort term Oral Inhalation0.043 mg/ m³General populationSystemic populationDNELLong term Inhalation0.022 mg/m³General populationSystemic populationPNELShort term Oral Inhalation0.022 mg		DNFI	Short term Dermal			Systemic
DNEL Inhalation DNEL Short term Dermal Inhalation DNEL Short term Dermal Inhalation DNEL Short term Dermal DNEL Short term Dermal Inhalation DNEL Short term DNEL Short term DNEL Short term DNEL Short term Inhalation DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term Inhalation DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term Inhalation DNEL Long term DNEL Long term DNEL Short term Oral DNEL Short term Oral DNEL DNEL DNEL DNEL DNEL <b< td=""><td></td><td>DINCE</td><td>Chort term Derma</td><td></td><td></td><td>Cysternio</td></b<>		DINCE	Chort term Derma			Cysternio
Inhalation Short term DermalInhalation 1.5 mg/kg bw/dayOpulation WorkersSystemicadipohydrazideDNEL Inhalation DNELLong term Inhalation1.76 mg/m³WorkersSystemicadipohydrazideDNEL Long termLong term Inhalation17.5 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNEL DNELLong term Dermal Inhalation0.345 mg/ 0.966 mg/ WorkersGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNEL DNEL Long termLong term Inhalation1.2 mg/m³ 0.021 mg/ WorkersGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNEL DNEL Long termLong term 0.021 mg/ Inhalation0.021 mg/ m³ WorkersGeneral populationSystemic Local2-methyl-2H-isothiazol-3-oneDNEL DNEL Long term0.021 mg/ NEL NEL Long termGeneral populationSystemic Local2-methyl-2H-isothiazol-3-oneDNEL DNEL Long termGeneral nabationSystemic populationLocal2-methyl-2H-isothiazol-3-oneDNEL DNEL Short term Inhalation0.021 mg/ m³General populationLocal2-methyl-2H-isothiazol-3-oneDNEL DNEL Short term0.043 mg/ n³General populationSystemic population2-methyl-2H-isothiazoln-3-one [EC no. 220-239-6] (3:1)DNEL DNEL Long termNota mg/ nabationGeneral nabationSystemic population3(3:1)DNEL LocalLong term nhalation n<		DNEL	Short term			Systemic
bw/daybw/dayadipohydrazideDNELLong term1.76 mg/m³WorkersSystemicadipohydrazideDNELShort term5.28 mg/m³WorkersSystemic1.2-benzisothiazol-3(2H)-oneDNELLong term17.5 mg/m³WorkersSystemic1.2-benzisothiazol-3(2H)-oneDNELLong term0.345 mg/ 0.966 mg/ WorkersGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term1.2 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term0.021 mg/ InhalationGeneral populationSystemic population2-methyl-2H-isothiazol-3-oneDNELLong term0.021 mg/ m³General populationLocal2-methyl-2H-isothiazol-3-oneDNELLong term0.021 mg/ m³General populationLocal2-methyl-2H-isothiazol-3-oneDNELLong term0.021 mg/ m³General populationLocalDNELLong term0.021 mg/ m³General populationLocalLocalDNELShort term0.043 mg/ m³General populationLocalDNELShort term Oral Inhalation0.02 mg/m³General populationLocalDNELLong term0.02 mg/m³General populationLocalDNELLong term0.02 mg/m³General populationLocalDNELLong term0.02 mg/m³General populationLocalDNELLong term0.				_		
DNEL Inhalation DNELLong term Inhalation Inhalation1.76 mg/m³WorkersSystemicadipohydrazideDNEL Long term InhalationDNEL Long term Dermal7.5 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNEL DNEL Long term Dermal0.345 mg/ g bw/day DNEL Long term Dermal0.345 mg/ g bw/day DNEL Long term DermalGeneral population WorkersSystemic2-methyl-2H-isothiazol-3-oneDNEL DNEL Long term InhalationLong term DNEL Long term Inhalation0.021 mg/ m³General population WorkersSystemic Systemic2-methyl-2H-isothiazol-3-oneDNEL DNEL Long term InhalationD.021 mg/ m³General populationLocal2-methyl-2H-isothiazol-3-oneDNEL DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Short term DNEL Short term DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL DNEL DNEL DNEL Long term Inhalation DNEL DNEL Long term DNEL Long term DNEL DNEL Long term DNEL Long term DNEL DNEL Long term DNEL DNEL DNEL Long term DNEL DNEL Long term DNEL DNEL Long term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNE		DNEL	Short term Dermal		Workers	Systemic
Inhalation Short term Inhalation5.28 mg/m³WorkersSystemicadipohydrazideDNELShort term Inhalation5.28 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ kg bw/dayGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation1.2 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationLocal population2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationLocal population2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.027 mg/ m³General populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Oral Inhalation0.053 mg/ populationSystemic populationLocalDNELShort term Oral Inhalation0.02 mg/m³General populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Inhalation0.02 mg/m³General populationLocalCocal <td></td> <td></td> <td></td> <td></td> <td></td> <td>Quatamia</td>						Quatamia
adipohydrazideDNELShort term Inhalation5.28 mg/m³WorkersSystemic11,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation17.5 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/m³General populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation1.2 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.027 mg/ kg bw/dayGeneral populationLocalDNELLong term Oral Inhalation0.027 mg/ kg bw/dayGeneral populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Oral Inhalation0.053 mg/ kg bw/dayGeneral populationLocalDNELShort term Oral Inhalation0.053 mg/ kg bw/dayGeneral populationLocalDNELLong term Inhalation0.02 mg/m³General populationLocalDNELShort term Oral Inhalation0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³General population		DNEL		1.76 mg/m ²	workers	Systemic
adipohydrazideInhalation17.5 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation1.2 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationSystemicDNELLong term Inhalation0.021 mg/ m³General populationSystemicDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Oral Inhalation0.02 mg/m³General populationLocalDNELShort term Oral Inhalation0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³General General populationLocal<		DNEL		5.28 mg/m ³	Workers	Systemic
InhalationOO1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term1.2 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term0.021 mg/ inhalationGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term0.021 mg/ inhalationGeneral populationSystemicDNELLong term0.021 mg/ inhalationGeneral populationLocalDNELLong term0.027 mg/ inhalationGeneral populationLocalDNELLong term Oral0.027 mg/ inhalationGeneral populationLocalDNELShort term0.043 mg/ inhalationGeneral populationLocalDNELShort term0.053 mg/ kg bw/dayGeneral populationLocalDNELShort term0.027 mg/ inhalationGeneral populationLocalDNELShort term0.043 mg/ inhalationGeneral populationLocalDNELShort term0.02 mg/m³General populationLocalInhalationDNELLong term0.02 mg/m³General populationInhalationDNELLong term0.02 mg/m³General populationInhalationDNELLong term0.02 mg/m³General population23:1)DNELLong term0.02 mg/m³General gopulation </td <td></td> <td></td> <td></td> <td>••g,</td> <td></td> <td>- ,</td>				••g,		- ,
1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term1.2 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term6.81 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term0.021 mg/ InhalationGeneral populationLocalDNELLong term0.021 mg/ InhalationGeneral populationLocalDNELLong term0.021 mg/ InhalationGeneral populationLocalDNELLong term0.027 mg/ kg bw/dayGeneral populationLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationLocalDNELShort term0.043 mg/ m³General populationLocalDNELShort term0.043 mg/ m³General populationLocalDNELShort term Oral0.053 mg/ kg bw/dayGeneral populationLocalDNELShort term Oral0.02 mg/m³General populationLocalInhalationm³DoveLocalDoveInhalationDNELLong term0.02 mg/m³General populationLocalDNELLong termDNELLong termLocalDove21.1DNELLong term0.02 mg/m³General populationLocal23.1DNELLong term0.02 mg/m³General po	adipohydrazide	DNEL		17.5 mg/m ³	Workers	Systemic
ParticipantDNELLong term Dermalkg bw/day 0.966 mg/ kg bw/daypopulation WorkersSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation6.81 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.027 mg/ kg bw/dayGeneral populationSystemicDNELLong term Oral0.043 mg/ m³General populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Oral0.053 mg/ kg bw/dayGeneral populationSystemic LocalDNELShort term Oral0.027 mg/m³General populationSystemic LocalInhalationm³0.023 mg/ m³General populationLocalInhalationDNELLong term Inhalation0.023 mg/ m³General populationLocal247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1)DNELLong term Long term0.02 mg/m³WorkersLocalDNELLong term Inhalation0.02 mg/m³General gonulationLocalDNELShort term0.02 mg/m³General gonulationLocal <td></td> <td></td> <td></td> <td>0.045 /</td> <td></td> <td></td>				0.045 /		
DNELLong term Dermal0.966 mg/ kg bw/dayWorkersSystemic2-methyl-2H-isothiazol-3-oneDNELLong term1.2 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term6.81 mg/m³WorkersSystemicDNELLong term0.021 mg/ InhalationGeneral populationLocalDNELLong term0.021 mg/ InhalationGeneral populationLocalDNELLong term0.027 mg/ kg bw/dayGeneral populationLocalDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.043 mg/ m³General populationLocalDNELShort term0.033 mg/ kg bw/dayGeneral populationLocalDNELShort term Oral0.033 mg/ kg bw/dayGeneral populationLocalDNELShort term Oral0.022 mg/m³General populationLocalDNELLong term0.02 mg/m³General populationLocalDNELLong term0.02 mg/m³General populationLocalInhalationDNELLong term0.02 mg/m³General populationLocalInhalationDNELLong term0.02 mg/m³General populationLocalInhalationDNELShort term0.02 mg/m³General populationLocalInhalationDNELShort term0.02 mg/m³General populationLocal	1,2-benzisothiazol-3(2H)-one	DNEL	Long term Dermal	•		Systemic
2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation1.2 mg/m³ populationGeneral populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Oral0.053 mg/ kg bw/dayGeneral populationLocalDNELShort term Oral0.053 mg/ n³General populationSystemic populationDNELLong term Inhalation0.053 mg/ n³General populationSystemic populationDNELLong term Inhalation0.02 mg/m³General populationLocal247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1)DNELLong term Inhalation0.02 mg/m³WorkersLocalDNELLong term InhalationDNELLong term Inhalation0.02 mg/m³General populationLocalDNELLong term InhalationD.02 mg/m³General populationLocalDNELNertLong term InhalationD.02 mg/m³Gene			Long term Dermal			Systemic
2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation1.2 mg/m³General populationSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation6.81 mg/m³WorkersSystemicDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.027 mg/ kg bw/dayGeneral populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Inhalation0.053 mg/ m³General populationLocalDNELShort term Oral Inhalation0.053 mg/ m³General populationSystemicDNELLong term Inhalation0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³General populationLocal247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6]DNELLong term Inhalation0.02 mg/m³WorkersLocal(3:1)DNELLong term Inhalation0.04 mg/m³General populationLocal		DINCE	Long term Derma	•	Workers	Oysternie
2-methyl-2H-isothiazol-3-oneInhalation Long term Inhalationpopulation WorkersSystemic2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.027 mg/ kg bw/dayGeneral populationLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Oral0.053 mg/ kg bw/dayGeneral populationSystemic populationDNELLong term Inhalation0.02 mg/m³General populationLocal247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1)DNELLong term Inhalation0.02 mg/m³WorkersLocalDNELLong term Inhalation0.02 mg/m³General populationLocalLocalDNELLong term Inhalation0.02 mg/m³General populationLocal		DNEL	Long term		General	Systemic
2-methyl-2H-isothiazol-3-oneInhalation Long term Inhalation0.021 mg/ m³ DNELGeneral populationLocal2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³ DNELGeneral populationLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Oral0.053 mg/ kg bw/dayGeneral populationLocalDNELShort term Oral0.02 mg/m³General populationLocalDNELShort term Oral0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³General populationLocal247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1)DNELLong term Inhalation0.02 mg/m³WorkersLocalDNELLong term InhalationDN2 mg/m³General populationLocalLocalDNELLong term Inhalation0.02 mg/m³General gopulationLocal			Inhalation	-		
2-methyl-2H-isothiazol-3-oneDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term0.027 mg/ msWorkersLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationSystemicDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.053 mg/ InhalationGeneral populationLocalDNELShort term Oral0.02 mg/m³General populationLocalInhalationDNELLong term0.02 mg/m³General populationLocalisothiazolin-3-one[EC no. 220-239-6] (3:1)DNELLong term Inhalation0.02 mg/m³WorkersLocalDNELLong term Inhalation0.02 mg/m³WorkersLocalLocalDNELLong term Inhalation0.02 mg/m³General populationLocal		DNEL	-	6.81 mg/m ³	Workers	Systemic
Inhalationm³populationDNELLong term0.021 mg/ m³WorkersLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationSystemicDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.053 mg/ InhalationGeneral populationLocalDNELLong term0.02 mg/m³General populationLocalDNELLong term0.02 mg/m³General populationLocalInhalationDNELLong term0.02 mg/m³General populationLocal247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1)DNELLong term Inhalation0.02 mg/m³WorkersLocalDNELLong term Inhalation0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³General populationLocal	0 mothed 01 lighthiand 0 and			0.001 mm/	Conorol	
DNEL Inhalation DNELLong term Inhalation DNEL0.021 mg/ m³WorkersLocalDNEL Inhalation DNELLong term Oral0.027 mg/ kg bw/dayGeneral population General populationSystemic LocalDNEL Inhalation DNELShort term Inhalation DNEL0.043 mg/ m³General populationLocalDNEL Inhalation DNELShort term Inhalation0.043 mg/ m³General populationLocalDNEL 4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6]DNEL DNELLong term Inhalation0.02 mg/m³ of termGeneral populationLocalDNEL (3:1)DNEL DNELLong term Inhalation0.02 mg/m³ of termWorkersLocalDNEL (3:1)DNEL DNELLong term Inhalation0.02 mg/m³ of termWorkersLocal	z-metnyi-zH-isotniazoi-3-one	DNEL				Local
Inhalationm³GeneralSystemicDNELLong term Oral0.027 mg/ kg bw/dayGeneralLocalDNELShort term0.043 mg/ InhalationGeneralLocalDNELShort term0.043 mg/ InhalationGeneralLocalDNELShort term0.043 mg/ InhalationWorkersLocalDNELShort term0.053 mg/ InhalationGeneralSystemicDNELShort term Oral0.053 mg/ InhalationGeneralSystemicDNELShort term Oral0.02 mg/m³GeneralLocal247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1)DNELLong term Inhalation0.02 mg/m³WorkersLocalDNELLong term Inhalation0.02 mg/m³WorkersLocalLocalDNELLong term Inhalation0.04 mg/m³General LocalLocal		DNEL				Local
Preaction mass of: 5-chloro-2-methyl- 4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 200-210-210-210-210-210-210-210-210-210-			-			
DNELShort term Inhalation0.043 mg/ m³General populationLocalDNELShort term Inhalation0.043 mg/ m³WorkersLocalDNELShort term Oral0.043 mg/ m³General populationLocalDNELShort term Oral0.053 mg/ kg bw/dayGeneral populationSystemicDNELDNELLong term Inhalation0.02 mg/m³General populationLocal247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1)DNELLong term Inhalation0.02 mg/m³WorkersLocalDNELLong term Inhalation0.02 mg/m³WorkersLocalLocal		DNEL	Long term Oral			Systemic
reaction mass of: 5-chloro-2-methyl- 4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1) DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Oral 0.02 mg/m ³ General population Local DNEL Long term Inhalation 0.02 mg/m ³ Workers Local Local Local DNEL Short term 0.02 mg/m ³ General population Local Local Local DNEL Short term 0.04 mg/m ³ General Local Local Local Local DNEL Short term 0.04 mg/m ³ General Local Local Local Local DNEL Short term 0.04 mg/m ³ General Local Local Local Local DNEL Short term 0.04 mg/m ³ General Local Local Local Local DNEL Short term 0.04 mg/m ³ General Local Loc						1 1
reaction mass of: 5-chloro-2-methyl- 4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1) DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term One term Inhalation DNEL Short term One term Inhalation DNEL Short term Inhalation DNEL Short term One term Inhalation DNEL Long term Inhalation DNEL Short term One term Inhalation DNEL Short term DNEL Short term DNEL Short term DNE Short term		DNEL				Local
reaction mass of: 5-chloro-2-methyl- 4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1) DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term 0.02 mg/m ³ Workers Local Local Local		DNFI				Local
reaction mass of: 5-chloro-2-methyl- 4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1) DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term 0.02 mg/m³ General population Local DNEL Long term Inhalation DNEL Short term 0.04 mg/m³ General Local		DITLE			Wontore	Loodi
reaction mass of: 5-chloro-2-methyl- 4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1) DNEL Long term Inhalation DNEL Short term 0.02 mg/m ³ General population 0.02 mg/m ³ General population UNEL Long term Inhalation 0.04 mg/m ³ General Local DNEL Local Local DNEL Local DNEL Short term 0.04 mg/m ³ General Local		DNEL	Short term Oral		General	Systemic
4-isothiazolin-3-one [EC no. Inhalation population 247-500-7] and 2-methyl-2H- Inhalation 0.02 mg/m³ isothiazol-3-one [EC no. 220-239-6] DNEL Long term (3:1) DNEL Long term 0.02 mg/m³ Workers Local DNEL Short term 0.04 mg/m³	, , , , , , , , , , , , , , , , , , , 					
(3:1) DNEL Long term 0.02 mg/m ³ Workers Local Inhalation DNEL Short term 0.04 mg/m ³ General Local	4-isothiazolin-3-one [EC no.	DNEL		0.02 mg/m ³		Local
DNELLong term Inhalation0.02 mg/m³WorkersLocalDNELShort term0.04 mg/m³GeneralLocal	isothiazol-3-one [EC no. 220-239-6]					
InhalationDNELShort term0.04 mg/m³GeneralLocal						
DNEL Short term 0.04 mg/m³ General Local		DNEL		0.02 mg/m ³	Workers	Local
				0.04 mailer3	Conoral	
e of issue/Date of revision : 30/08/2023 Date of previous issue : 04/10/2022 Version : 2 7/				1 U.U4 IIIQ/M°	General	LOCAL
		DINEL		U U		

SECTION 8: Exposure controls/personal protection					
	Inhalation		population		
DNEL	Short term	0.04 mg/m ³	Workers	Local	
	Inhalation				
DNEL	Long term Oral	0.09 mg/	General	Systemic	
		kg bw/day	population		
DNEL	Short term Oral	0.11 mg/ kg bw/day	General population	Systemic	

PNECs

No PNECs available

8.2 Exposure controls		
Appropriate engineering controls	: Good general ventilation should be sufficient to control worker exposure to a contaminants.	irborne
Individual protection meas	<u>es</u>	
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products before eating, smoking and using the lavatory and at the end of the working Appropriate techniques should be used to remove potentially contaminated of Contaminated work clothing should not be allowed out of the workplace. Wa contaminated clothing before reusing. Ensure that eyewash stations and satisfies are close to the workstation location.	period. clothing. ash
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a assessment indicates this is necessary to avoid exposure to liquid splashes, gases or dusts. If contact is possible, the following protection should be wor unless the assessment indicates a higher degree of protection: safety glass side-shields.	mists, n,
Skin protection		
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard be worn at all times when handling chemical products if a risk assessment in this is necessary. Considering the parameters specified by the glove manufacheck during use that the gloves are still retaining their protective properties. should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consistin several substances, the protection time of the gloves cannot be accurately estimated.	ndicates acturer, . It
	Recommendations : Wear suitable gloves tested to EN374.	
	> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm	
	Not recommended polyvinyl alcohol (PVA) gloves	
Body protection	: Personal protective equipment for the body should be selected based on the being performed and the risks involved and should be approved by a special before handling this product.	task ist
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and shou approved by a specialist before handling this product.	
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that mee appropriate standard or certification. Respirators must be used according to respiratory protection program to ensure proper fitting, training, and other im aspects of use.	a
Environmental exposure controls	 Filter type (spray application): A P Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legisla In some cases, fume scrubbers, filters or engineering modifications to the prequipment will be necessary to reduce emissions to acceptable levels. 	ation.

: 30/08/2023 Date of previous issue

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

<u>Appearance</u>	
Physical state	: Liquid.
Colour	: Various
Odour	: Slight
Odour threshold	: Not available.
Melting point/freezing point	: Not available.
Initial boiling point and boiling range	:

Ingredient name	°C	°F	Method
water	100	212	
Ethyldiglycol	196	384.8	

Flammability

: Not available.

- Lower and upper explosion : Kower: 1.2%
 - Upper: 23.5%

ŝ

Flash point

limit

: Closed cup: >100°C (>212°F)

Auto-ignition temperature

Ingredient name	°C	°F	Method
₽ thyldiglycol	204	399.2	

Decomposition temperature pH Viscosity Solubility(ies) Not available.	 Not available. 8.2 to 8.8 [Conc. (% w/w): 100%] Not available.
Solubility in water Partition coefficient: n-octanol/ water	Not available.Not applicable.

ŝ,

Vapour pressure

	Va	Vapour Pressure at 20°C			e at 20°C Vapour pressure		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method	
water	17.5	2.3					
Ethyldiglycol	0.14	0.019					

Relative density	: Not available.
Density	: 1.2 g/cm ³
Vapour density	: Not available.
Explosive properties	: Not available.
Oxidising properties	: Not available.
Particle characteristics	
Median particle size	: Not applicable.

SECTION 10: Stabilit	y and reactivity
10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: No specific data.
10.5 Incompatible materials	: No specific data.
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008 Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
riodo-2-propynyl-butyl carbamate	LC50 Inhalation Dusts and mists	Rat	0.67 g/m³	4 hours
	LC50 Inhalation Dusts and mists	Rat	0.763 mg/l	4 hours
	LD50 Dermal	Rat	>2000 mg/kg	-
	LD50 Oral	Rat	400 mg/kg	-
4,5-dichloro-2-octyl-2H- isothiazol-3-one	LC50 Inhalation Dusts and mists	Rat - Male, Female	0.26 mg/l	4 hours
	LD50 Dermal	Rabbit	>652 mg/kg	-
	LD50 Oral	Rat	1585 mg/kg	-
1,2-benzisothiazol-3(2H)- one	LD50 Oral	Rat	1020 mg/kg	-
2-methyl-2H-isothiazol- 3-one	LC50 Inhalation Dusts and mists	Rat	0.11 mg/l	4 hours
reaction mass of: 5-chloro- 2-methyl-4-isothiazolin-	LD50 Oral	Rat	53 mg/kg	-
3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-				
3-one [EC no. 220-239-6] (3: 1)				

Conclusion/Summary

: Based on available data, the classification criteria are not met.

Acute toxicity estimates

Route	ATE value
halation (vapours) Inhalation (dusts and mists)	580.21 mg/l 333.03 mg/l

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
ti tanium dioxide	Skin - Mild irritant	Human	-	72 hours 300	-
				ug l	
2-Butoxyethanol	Eyes - Moderate irritant	Rabbit	-	24 hours 100	-
-				mg	
	Eyes - Severe irritant	Rabbit	-	100 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
3-iodo-2-propynyl-butyl carbamate	Eyes - Severe irritant	Rabbit	-	-	-
2,4,7,9-tetramethyl- 5-decyne-4,7-diol	Eyes - Severe irritant	Rabbit	-	0.1 MI	-
3	Skin - Mild irritant	Rabbit	-	0.5 g	-
1,2-benzisothiazol-3(2H)-one	Skin - Mild irritant	Human	-	48 hours 5 %	-
ate of issue/Date of revision	: 30/08/2023 Date of previo	us issue : 04	/10/2022	Versi	ion : 2 10/17
QUATOP 2760-03 - All variant	ts			Label I	No : <mark>#</mark> 9664

SECTION 11: Toxicol	ogical information					
reaction mass of: 5-chloro- 2-methyl-4-isothiazolin- 3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol- 3-one [EC no. 220-239-6] (3:	Skin - Severe irritant	Human	-	0.01 %	-	

Conclusion/Summary

: Based on available data, the classification criteria are not met.

Sensitisation

Product/ingredient name	Route of exposure	Species	Result
3-iodo-2-propynyl-butyl carbamate	skin	Guinea pig	Not sensitizing

Conclusion/Summary : May cause an allergic skin reaction.

Mutagenicity

Product/ingredient name	Test	Experiment	Result
3-iodo-2-propynyl-butyl carbamate		Experiment: In vitro Subject: Bacteria	Negative

Conclusion/Summary : Based on available data, the classification criteria are not met.

Carcinogenicity

It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

Conclusion/Summary

Based on available data, the classification criteria are not met.

Reproductive toxicity

Product/ingredient name	Maternal toxicity	Fertility	Developmental toxin	Species	Dose	Exposure
3-iodo-2-propynyl-butyl carbamate	Negative	-	Negative	Rabbit - Female	Oral: 20 mg/kg	13 days; 7 days per week
	Positive	-	Negative	Rabbit - Female	Oral: 50 mg/kg	13 days; 7 days per week

Conclusion/Summary : Based on available data, the classification criteria are not met.

Teratogenicity

Product/ingredient name	Result	Species	Dose	Exposure
3-iodo-2-propynyl-butyl carbamate	Negative - Oral	Rabbit - Female	50 mg/kg	-

Conclusion/Summary : Based on available data, the classification criteria are not met.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
3-iodo-2-propynyl-butyl carbamate	Category 1	-	larynx

Aspiration hazard

Not available.

Information on likely routes : Not available.

of exposure

Eye contact

Inhalation

re

Potential acute health effects

: No known significant effects or critical hazards.

: No known significant effects or critical hazards.

:04/10/2022

SECTION 11: Toxico	-
Skin contact	: May cause an allergic skin reaction.
Ingestion	: No known significant effects or critical hazards.
Symptoms related to the phy	sical, chemical and toxicological characteristics
Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.
Delayed and immediate effect	ts as well as chronic effects from short and long-term exposure
Short term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
<u>Long term exposure</u>	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health eff	ects
Not available.	
Conclusion/Summary	: Not available.
General	: Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.

11.2 Information on other hazards

- 11.2.1 Endocrine disrupting properties
- Not available.

11.2.2 Other information

Not available.

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
iitanium dioxide	Acute LC50 3 mg/l Fresh water	Crustaceans - Ceriodaphnia dubia - Neonate	48 hours
	Acute LC50 6.5 mg/l Fresh water	Daphnia - <i>Daphnia pulex</i> - Neonate	48 hours
	Acute LC50 >1000000 μg/l Marine water	Fish - Fundulus heteroclitus	96 hours
2-Butoxyethanol	Acute EC50 >1000 mg/l Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
	Acute LC50 800000 µg/l Marine water	Crustaceans - Crangon crangon	48 hours
	Acute LC50 1250000 µg/l Marine water	Fish - Menidia beryllina	96 hours
3-iodo-2-propynyl-butyl carbamate	Acute EC50 0.022 mg/l Fresh water	Algae - Scenedemus subspicatus	72 hours
	Acute EC50 0.16 mg/l Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
	Acute LC50 0.067 mg/l Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Acute NOEC 0.049 mg/l Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Chronic NOEC 0.05 mg/l Fresh water	Daphnia - Daphnia Magna	21 days
2,4,7,9-tetramethyl- 5-decyne-4,7-diol	EC50 91 mg/l	Daphnia - <i>Daphnia magna</i>	48 hours
ate of issue/Date of revision	: 30/08/2023 Date of previous issue	: 04/10/2022 Version	:2 12/17
QUATOP 2760-03 - All varia	nts	Label No	4 9664

SECTION 12: Ecological information

/prinus carpio	96 hours
Pseudokirchneriella	72 hours
ata	
Skeletonema costatum	96 hours
- Daphnia magna	48 hours
eans - Gammarus pulex	48 hours
ncorhynchus mykiss	96 hours
Nitzschia pungens	96 hours
ncorhynchus mykiss	97 days
Skeletonema Costatum	72 hours
- Daphnia Magna	48 hours
norhynchus Mykiss	96 hours
Skeletonema Čostatum	72 hours
- Daphnia magna	48 hours
ncorhynchus mykiss	96 hours
	, 0

12.2 Persistence and degradability

Product/ingredient name	Test	Result		Dose	Inoculum
₱,2-benzisothiazol-3(2H)-one	EU	24 % - 28 days		-	-
Conclusion/Summary	: This product ha	as not been tested for	biodegrada	ation.	
Product/ingredient name	Aquatic half-life		Photolysis	5	Biodegradability
-iodo-2-propynyl-butyl carbamate 1,2-benzisothiazol-3(2H)-one	-		-		Not readily Inherent

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
2-Butoxyethanol	0.81	-	Low
3-iodo-2-propynyl-butyl carbamate	>1	-	Low
1,2-benzisothiazol-3(2H)-one	-	3.2	Low

12.4 Mobility in soil	
Soil/water partition	: Not available.
coefficient (Koc)	
Mobility	: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Endocrine disrupting properties

Not available.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment met	hods
Product	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
European waste catalogue (EWC)	: 080111*, 200127*
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	ADN	IMDG	ΙΑΤΑ
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

14.6 Special precautions for user: **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Maritime transport in : Not relevant/applicable due to nature of the product. **bulk according to IMO instruments**

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>EU Regulation (EC) No. 1907/2006 (REACH)</u>

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Date of issue/Date of revision AQUATOP 2760-03 - All variants : 30/08/2023 Date of previous issue

:04/10/2022

SECTION 15: Regulatory information

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Product/ingredient name	%	Designation [Usage]
A QUATOP 2760-03	≥90	3

Labelling	1 · · · · · · · · · · · · · · · · · · ·
Other EU regulations	
Industrial emissions (integrated pollution prevention and control) - Air	: Not listed
Industrial emissions (integrated pollution prevention and control) - Water	: Not listed
Explosive precursors	: Not applicable.
Ozone depleting substanc Not listed.	<u>es (1005/2009/EU)</u> :
Prior Informed Consent (P Not listed.	<u>'IC) (649/2012/EU)</u>
Persistent Organic Polluta Not listed.	<u>ints</u>
Seveso Directive	
This product is not controlled	d under the Seveso Directive.
International regulations	
Chemical Weapon Convent Not listed.	ion List Schedules I, II & III Chemicals
Montreal Protocol Not listed.	

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

15.2 Chemical safety assessment : This product contains substances for which Chemical Safety Assessments are still required.

SECTION 16: Other information

✓ Indicates information that has changed from previously issued version.

Abbreviations and acronyms	 ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative
Date of issue/Date of revision	: 30/08/2023 Date of previous issue : 04/10/2022 Version : 2 15/17

SECTION 16: Other information

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Skin Sens. 1, H317	Calculation method
Aquatic Chronic 3, H412	Calculation method

Full text of abbreviated H statements

	Sievialeu in statements
⊮ 301	Toxic if swallowed.
H302	Harmful if swallowed.
H310	Fatal in contact with skin.
H311	Toxic in contact with skin.
H314	Causes severe skin burns and eye damage.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H331	Toxic if inhaled.
H351	Suspected of causing cancer.
H372	Causes damage to organs through prolonged or repeated exposure.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
EUH071	Corrosive to the respiratory tract.

Full text of classifications [CLP/GHS]

Acute Tox. 2	ACUTE TOXICITY - Category 2
Acute Tox. 3	ACUTE TOXICITY - Category 3
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Aquatic Chronic 2	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
Carc. 2	CARCINOGENICITY - Category 2
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Skin Corr. 1	SKIN CORROSION/IRRITATION - Category 1
Skin Corr. 1B	SKIN CORROSION/IRRITATION - Category 1B
Skin Corr. 1C	SKIN CORROSION/IRRITATION - Category 1C
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
Skin Sens. 1A	SKIN SENSITISATION - Category 1A
Skin Sens. 1B	SKIN SENSITISATION - Category 1B
STOT RE 1	SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 1
Date of issue/ Date of	: 30/08/2023
revision	
Date of previous issue	e : 04/10/2022
Version	: 2

AQUATOP 2760-

Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision AQUATOP 2760-03 - All variants : 30/08/2023 Date of previous issue